Cargando…
The combination of MnO(2)@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer
It can be found from a large number of cancer treatments that use of anti-cancer drugs alone often presents low efficacy and high side effects. This study aims to develop a new drug carrier with tumor-specific response, controlled release in vivo and high tumor-suppressive property. Inorganic nano-m...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843201/ https://www.ncbi.nlm.nih.gov/pubmed/35147070 http://dx.doi.org/10.1080/10717544.2022.2032872 |